auris
medical
announces
initiation
part
b
travers
phase
study
vertigo
hamilton
bermuda
october
auris
medical
holding
nasdaq
ears
company
dedicated
developing
therapeutics
address
important
unmet
medical
needs
neurotology
central
nervous
system
disorders
today
announced
first
patient
randomized
part
b
travers
phase
trial
intranasal
betahistine
acute
vertigo
follows
positive
interim
analysis
part
study
early
september
completion
enrollment
oral
treatment
group
receipt
regulatory
clearance
part
b
first
three
participating
study
countries
part
b
travers
trial
company
enroll
patients
suffer
acute
vertigo
following
neurosurgery
randomized
receive
either
mg
intranasal
betahistine
placebo
three
times
daily
four
weeks
improvement
standing
foam
test
baseline
day
primary
efficacy
endpoint
improvement
tandem
romberg
test
day
two
weeks
completion
treatment
key
secondary
efficacy
endpoint
two
tests
measure
long
patients
able
maintain
balance
foam
mat
two
feet
aligned
one
respectively
eyes
closed
company
remained
blinded
treatment
allocation
interim
analysis
corresponding
data
part
pooled
part
b
part
travers
trial
demonstrated
good
safety
tolerability
observed
compelling
dose
response
effect
active
treated
patients
showing
times
better
performance
key
balance
tests
commented
thomas
meyer
auris
medical
founder
chairman
ceo
part
b
aim
confirm
positive
outcomes
two
highest
doses
larger
patient
sample
based
results
advance
program
phase
development
patients
suffering
vertigo
regaining
balance
quickly
possible
utmost
importance
unlike
vertigo
drugs
suppress
vestibular
function
treat
symptoms
nausea
acts
vestibular
stimulant
enhance
accelerate
vestibular
compensation
help
patients
get
back
feet
company
expects
complete
enrollment
part
b
travers
trial
end
first
quarter
provided
pandemic
cause
restrictions
patient
enrollment
betahistine
betahistine
small
molecule
structural
analog
histamine
acts
agonist
h
antagonist
h
histamine
receptors
unlike
histamine
crosses
known
enhance
inner
ear
cerebral
blood
flow
increase
histamine
turnover
enhance
histamine
release
brain
increase
release
acetylcholine
dopamine
norepinephrine
brain
result
general
brain
arousal
compound
good
safety
profile
yet
also
known
clinical
utility
held
back
poor
bioavailability
intranasal
administration
betahistine
shown
result
times
higher
bioavailability
intranasal
betahistine
developed
project
code
treatment
acute
vertigo
betahistine
shown
increase
cochlear
vestibular
cerebral
blood
flow
facilitate
vestibular
compensation
inhibit
neuronal
firing
vestibular
nuclei
betahistine
oral
administration
approved
countries
us
notable
exception
treatment
vertigo
meniere
disease
auris
medical
auris
medical
biopharmaceutical
company
dedicated
developing
therapeutics
address
important
unmet
medical
needs
neurotology
cns
disorders
company
focused
development
intranasal
betahistine
treatment
vertigo
phase
prevention
weight
gain
somnolence
post
phase
company
developing
nasal
spray
protection
airborne
pathogens
allergens
addition
auris
medical
two
phase
programs
development
acute
inner
ear
hearing
loss
acute
inner
ear
tinnitus
company
founded
headquartered
hamilton
bermuda
main
operations
basel
switzerland
shares
auris
medical
holding
trade
nasdaq
capital
market
symbol
statements
press
release
may
contain
statements
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
statements
statements
historical
facts
may
include
statements
address
future
operating
financial
business
performance
auris
medical
strategies
expectations
cases
identify
statements
words
may
might
expects
plans
anticipates
believes
estimates
predicts
projects
potential
outlook
continue
negative
terms
comparable
terminology
statements
based
management
current
expectations
beliefs
involve
significant
risks
uncertainties
could
cause
actual
results
developments
business
decisions
differ
materially
contemplated
statements
risks
uncertainties
include
limited
auris
medical
need
ability
raise
substantial
additional
funding
continue
development
product
candidates
ability
pursue
strategic
partnering
funding
phase
programs
results
auris
medical
review
strategic
options
outcome
action
taken
result
review
timing
conduct
clinical
trials
auris
medical
product
candidates
clinical
utility
auris
medical
product
candidates
timing
likelihood
regulatory
filings
approvals
auris
medical
intellectual
property
position
auris
medical
financial
position
including
impact
future
acquisitions
dispositions
partnerships
license
transactions
changes
auris
medical
capital
structure
including
future
securities
offerings
risks
uncertainties
also
include
limited
described
caption
risk
factors
auris
medical
annual
report
form
year
ended
december
auris
medical
filings
sec
available
free
charge
securities
exchange
commission
website
one
risks
uncertainties
materialize
underlying
assumptions
prove
incorrect
actual
results
may
vary
materially
indicated
statements
subsequent
written
oral
statements
attributable
auris
medical
persons
acting
behalf
auris
medical
expressly
qualified
entirety
reference
risks
uncertainties
place
undue
reliance
statements
statements
speak
date
made
auris
medical
undertake
obligation
update
light
new
information
future
developments
otherwise
except
may
required
applicable
law
investor
contact
joseph
green
edison
advisor
auris
medical
jgreen
investors
